Table 1.
Patients’ clinical characteristics and pharmacological treatment
| Characteristics | Total pts (no. = 96) | SR (no. = 62) | AF (no. = 34) |
|---|---|---|---|
| Age (years) | 73 (67–77) | 72.5 (66.8–76.3) | 73 (66.8–78.3) |
| BMI (kg/m2) | 28.4 ± 3.89 | 28.4 (25.9–30.8) | 28.2 (25.5–31.3) |
| CHA2DS2VASc | 3 (2–4) | 3 (2–4) | 3 (2–4) |
| Sex (M/F) | 66/30 | 45/17 | 21/13 |
| Underlined cardiopathy (no. of pts) | |||
| Hypertensive | 55 | 37 | 18 |
| Hypertrophic | 1 | 1 | 0 |
| Post-ischaemic | 3 | 3 | 0 |
| Dilatative | 5 | 2 | 3 |
| Mild-reduced EF | 3 | 2 | 1 |
| Valvular | 4 | 3 | 1 |
| No other than AF | 25 | 17 | 8 |
| AF history duration (months)—unknown in 56 pts | 4.9 ± 2.9 | 5.0 ± 2.5 | 4.8 ± 2.1 |
| Oral medical treatment (no. of pts) | |||
| Amiodarone | 56 | 37 | 19 |
| Propafenone | 13 | 10 | 3 |
| Flecainide | 12 | 7 | 5 |
| Sotalol | 4 | 4 | 0 |
| Digoxin | 22 | 14 | 8 |
| Beta-blockers | |||
| Bisoprolol | 47 | 31 | 16 |
| Metoprolol | 4 | 4 | 0 |
| Carvedilol | 4 | 2 | 2 |
| Nebivolol | 7 | 3 | 4 |
| Atenolol | 4 | 4 | 0 |
| Ca++ channel blockers | |||
| Verapamil | 2 | 2 | 0 |
| Ace inhibitors | 31 | 22 | 9 |
| MRA | 20 | 13 | 7 |
| VKA | 74 | 52 | 22 |
| NOA | 22 | 10 | 12 |
| Comorbidities (no. of pts) | |||
| COPD | 6 | 1 | 5 |
| OSAS | 4 | 3 | 1 |
| CKD (GFR < 50 ml/min) | 14 | 9 | 5 |
| Metabolic disease | 61 | 39 | 22 |
| Current smoking | 6 | 3 | 3 |
| Bundle branch block | 9 | 7 | 2 |
| Hypertension | 80 | 52 | 28 |
| Diabetes | 19 | 12 | 7 |
AF atrial fibrillation, F female, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, EF ejection fraction, M male, MRA mineralocorticoid receptor antagonist, NOA new oral anticoagulants, OSAS obstructive sleep apnea syndrome, SR sinus rhythm, VKA Vitamin K antagonist